Analytik Jena AG

ots Ad hoc-Service: Analytik Jena AG Analytik Jena buys patents for bioanalytical equipment system Analytik Jena secures world-wide rights to PHOTOCHEM

Ad hoc-announcement edited and sent by DGAP. The sender is solely responsible for the contents of this announcement. -----------------------------------------------------

    Jena/Berlin (ots Ad hoc-Service) - Analytik Jena AG (Neuer Markt: AJA), specialising in the development and the production of analytical and bioanalytical analysis systems, has signed a contract with FAT Forschungsinstitut für antioxidative Therapie GmbH in Berlin for the sale of the world-wide patents and of the know-how for the production of bioanalytical systems on the basis of photosensitised chemiluminescence. They are used for the control of the integral anti-oxidative capacity of substance mixtures such as blood plasma, food, cosmetics and pharmaceutical products as well as for the assessment of the anti-radical characteristics of individual substances (radicals are, among other things carcinogenic substances). The purchase price is DM 2.1 million.

    By means of the photochemiluminescence method, the fast photochemical stimulation of radical formation is combined with the sensitive luminometric detection. The advantages of this highly efficient technology are, on the one hand, the reduction of the analysis times by a factor of approx. 60 and, on the other hand, the very high sensitivities in the range of nanomolar concentrations of non-enzymatic anti-oxidative substances.

    Besides the patents to this unique technology for quantifying anti-oxidative capacities into water and lipid soluble substances quickly, at low cost and in an environmentally compatible way, the contract with FAT GmbH simultaneously comprises the world-wide rights for the production of the necessary test kits. The opinions of the experts evidence unanimously the outstanding meaning of the assessment of the anti-oxidative status of biological material with a world-wide market volume of several million US dollars per annum with a clearly rising tendency over the coming years. Klaus Berka, CEO of the Analytik Jena Group, "The strategic aim of this acquisition of PHOTOCHEM was to expand and to consolidate our position in the field of bioanalysis. Today we already have a wide-ranging technology platform for the future growth sectors. Thus we are also in a position, to make use of previous experience and results of equipment research for the development of really effective and favourably priced automated systems for all fields of analysis." Thomas Fritsche, Investor Relations Manager at Analytik Jena: "We have promised our shareholders growth in all segments. With the rights to the production and world-wide sale of this bioanalytical measuring system as well as the associated reagent kit ready for application, by means of which we will considerably strengthen our future consumable business, we are securing our future growth with the expansion of our technology platform." "By means of these patents we are now in the position to more strongly enlarge our range of products and services for the applications in the fields of medicine, foodstuffs, pharmaceuticals, biotechnology and environmental analysis", Klaus Berka said.

    In the bioanalytical solutions division, Analytik Jena produce and sell various technologies for the characterisation and quantification of low and high molecular biomolecules. Here, besides instrumental analysis such as molecular and mass spectroscopy, above all the methods of molecular biology have a high level of relative importance e.g. for the analysis of nucleic acids and proteins. Analytik Jena focus their activities in order to provide effective platform technologies and methods for the fields of the environment, biochemistry, pharmaceuticals, genetics, biomedicine and immunology. In that way Analytik Jena offers, with the business unit, the decisive tools for research and development of innovative products in biotechnology and is thus closely involved in the success in this rapidly developing business sector. Analytik Jena AG make, at the Jena location with their core competence in instrumental analysis, optics and microelectronics and the expertise in biotechnology, an important contribution in the creative environment of the BioInstrument-Conception of the BioRegio of Thuringia. Since July 3, 2000, Analytik Jena AG (WKN 521350) has been quoted on the Neuer Markt of the Frankfurt Stock Exchange.


    Thomas Fritsche Investor Relations Analytik Jena AG Phone: +49-3641-201-281 Fax: +49-3641-201-260

End ----------------------------------------------------- Internet:

Original-Content von: Analytik Jena AG, übermittelt durch news aktuell

Weitere Meldungen: Analytik Jena AG

Das könnte Sie auch interessieren: